



## Global Research & Development

THIS DOCUMENT CONTAINS CONFIDENTIAL AND/OR TRADE SECRET INFORMATION THAT IS DISCLOSED ONLY IN CONNECTION WITH THE LICENSING AND/OR REGISTRATION OF PRODUCTS FOR PFIZER INC OR ITS AFFILIATED COMPANIES. THIS DOCUMENT SHOULD NOT BE DISCLOSED OR USED, IN WHOLE OR IN PART, FOR ANY OTHER PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF PFIZER INC.

15 July 2011

**Re: Withdrawal of Macugen (pegaptanib sodium) type II variation  
EMA/H/C/620/II/44**

Dear Dr. Abadie,

I would like to inform you that, at this point of time, Pfizer Limited has taken the decision to withdraw the application for a new indication for Macugen 0.3 mg solution for injection in the *'treatment of visual impairment due to diabetic macular oedema (DME).'*

The withdrawal is based on the following reason:  
The CHMP's preliminary assessment on the data provided thus far does not allow the Committee to conclude on a positive benefit risk balance.

The decision will not have consequences for patients enrolled in any ongoing Pfizer sponsored Macugen clinical trials, at this point in time.

Following withdrawal, Pfizer intends to further evaluate the available data and we reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

Yours sincerely,

On behalf of Pfizer Limited.

